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Abstract 
 
DNA ligases ascertain and facilitate genomic integrity by ensuring 
DNA repair during synthesis and replication. One of the most lethal 
forms of DNA damage is a double strand break which can lead to loss 
of more than 100 million base pairs of genetic information. The Non 
Homologous End Joining (NHEJ) DNA repair pathway is sequence 
independent and involves recruitment of several proteins such as 
Ku70/80, Artemis, DNA-PKcs, Ligase 4 and XRCC4 for ligation and 
repair of the broken double strand DNA ends. Evidence in the 
literature suggests that some of the key players in the NHEJ pathway 
have distinct roles in cancer and in addition contribute to development 
of resistance to chemo-radiotherapy.  
 
Several studies indicate that disruption of the LIG4 gene(DNA ligase 4)  
- a critical component of the NHEJ pathway, results in increased 
sensitivity of cells to ionizing irradiation. In this study we have explored 
the relevance DNA Ligase 4 in Chronic Lymphocytic Leukemia (CLL). 
Using endpoint PCR analysis we detect the expression of LIG1, LIG3 
and LIG4 genes in a small cohort of primary CLL cases. Protein 
expression of Ligase 4 was detected in HeLa (positive control), MEC1 
(a CLL line) cells and in a random cohort of CLL cases. Surprisingly, 
Ligase 4 and XRCC4 protein expression did not alter in response to 
irradiation (3 Gy and 5 Gy) in MEC1 or HeLa cells.  
 
SCR7, a specific inhibitor of Ligase 4, was used to study cell 
cytotoxicity in response to irradiation. Both MEC1 and Daudi cells 
showed increased cell death upon treatment with high concentrations 
(250 µM) of the drug alone. Radiosensitivity experiments using SCR7 
 ii 
 
(10 µM and 100 µM) treatment prior to irradiation of cells showed no 
significant change in cell death in both MEC1 cells and Daudi cells at 
sequential time points. Although the results generated during this 
study provide some insights into the expression of certain DNA repair 
components in CLL, a longer and more substantive study in a larger 
cohort of patient samples is required for more definitive conclusions to 
address the relevance in CLL.  
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Chapter 1: Introduction 
 
Keeping our genome intact is vital for faithful transfer of genetic 
information from one generation to another, as our genome is 
subjected to several external and endogenous insults, which cause 
damage of Deoxyribonucleic acid (DNA) resulting in harmful mutations 
and diseases including cancer1.  
1.1 Sources of DNA damage 
DNA damage is mainly caused by environmental factors such as 
ultraviolet (UV) rays, ionising radiation (IR), genotoxic substances (for 
example, those present in cigarettes) and alkylating agents. These 
agents cause aberrations in the DNA sequence producing both Single 
Strand Breaks (SSB) and Double Strand Breaks (DSB)2. IR can 
damage DNA directly and indirectly. In most instances the radiation 
energy is directly absorbed by the DNA resulting in ionisation and 
breakage of the DNA strand3. As the majority of biological systems are 
made of water, the by-products released on irradiation of water are 
indirect sources of DNA damage. Radiolysis of water produces 
reactive species such as hydroxyl radicals (superoxide and peroxide 
radicals), which attack the DNA bases and sugars and form a wide 
variety of lesions, mainly DSBs2,4,5. A DSB is produced when two or 
 2 
more hydroxyl radicals attack both the strands of DNA. In a typical 
reaction of IR with DNA, initially, a water molecule is ionised due to 
high ionising energy. The water molecule loses a proton to generate a 
hydroxyl radical (• HO). The activated electron reacts further with 
oxygen to produce a superoxide radical (O2•). There are reported 
incidences of the hydroxyl radical attacking one strand of the DNA and 
then getting transported to the next strand to cause damage as 
electronic charges generated from IR can travel through long 
distances across the DNA helix2,6. Secondly, cellular metabolism 
results in fragmentation, base loss, and SSBs of DNA due to the 
release of reactive oxygen species (ROS) such as hydroxyl radicals; 
superoxide anions and hydrogen peroxide, thereby causing oxidative 
damage7. In addition, spontaneous decay of the primary structure of 
DNA under certain conditions such as DNA hydrolysis, DNA oxidation 
and non-enzymatic methylation of DNA, gives rise to DNA breakage8. 
Replication errors during DNA synthesis are also responsible for 
causing nucleotide mismatches in DNA during the S phase of the cell 
cycle, resulting in the generation of insertions and deletions in the DNA 
helix9.  
1.2 DNA Repair Mechanisms 
There are several different DNA repair mechanism systems in 
 3 
mammals which are triggered in response to the type of DNA damage. 
They are: Base Excision Repair (BER), Nucleotide Excision Repair 
(NER), Mismatch Repair (MMR), Homologous Recombination (HR) 
and Non Homologous End Joining (NHEJ) (Fig 1). 
 
                                                                                                          
Figure 1: Pictorial representation of various DNA Damaging 
agents generating a wide variety of DNA lesions including SSBs, 
DSBs, insertions and deletions which require or trigger repair 
machinery (adapted from Hoejimakers JH et al., 2001) 1. 
    
DNA damage in the form of SSBs, mismatched bases, insertions, 
deletions, and addition of bulky adducts is repaired by BER, NER and 
MMR. In contrast, the two main pathways that have evolved to counter 
DSBs generated inadvertently are HR and NHEJ2. 
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1.2.1 Base Excision Repair (BER) 
Many of the DNA lesions in the form of SSBs and abasic sites which 
are repaired by BER, are formed by oxidative stress, alkylating agents  
and spontaneous reactions of DNA2,10. In BER, the damaged base is 
excised using the DNA glycosylases, which help in removing the 
chemically altered base from DNA by hydrolysing the N-glycosidic 
bonds11. To further remove the abasic, apurinic or apyrimidinic sites 
(AP), the apurinic or apyridimidinic endonucleases are recruited on the 
AP site; in mammals, AP endonuclease (APE1) is the most commonly 
recruited endonuclease. The AP sites are incised by APE1 
endonuclease which cuts through the phospho- backbone of DNA12. 
After excising the abasic site, other enzymes including 2-deoxyribose 
phosphodiesterase (dRP), DNA polymerase, DNA Ligase 1 and DNA 
Ligase 3 assist in the synthesis and repair10. There are two different 
types of BER pathways; one is the ‘short patch repair’ that helps in the 
replacement of a single nucleotide, whereas, the ‘long patch repair’ 
helps in the replacement of a series of nucleotides13. 
1.2.2 Nucleotide Excision Repair (NER) 
NER is responsible for the repair of bulky DNA lesions produced as a 
result of genotoxic chemicals and UV light. NER operates via two 
distinct pathways: Global Genomic Repair (GGR) and Transcription-
Coupled Repair (TCR)14. GGR is transcription independent and 
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removes DNA adducts from the non-transcribed portions of the 
genome, whereas, TCR repairs transcription-hindering lesions of   
DNA15. Approximately 30 proteins are involved for successful 
completion of NER, with the essential ones being: Xeroderma 
Pigmentosum Complementation group C protein complex (XPC-
HR23B), Xeroderma Pigmentosum Complementation group A (XPA), 
Replication Protein A (RPA), DNA Damage-Binding protein 1 
(DDB1), DNA Damage-Binding protein 2 (DDB2), Transcription Factor 
II Human (TFIIH) and Cockayne syndrome group A and B genes 
(CSA and CSB). XPC-HR23B aids in identifying the lesions in GGR, 
whereas in TCR, Ribonucleicacid polymerase II helps in identifying the 
damaged area. TFIIH is recruited in the next step in both of the 
processes, to open up the DNA helix around the lesion. Other 
cofactors, namely CSA and CSB are recruited to make the lesion more 
accessible to the next set of repair proteins16. XPA stabilises the 
opened helix around the lesion and the RPA protein’s major function is 
to safeguard the intact DNA   strand17,18. During both repair 
mechanisms, the DNA is resynthesised by Polymerase epsilon(Polε) 
or Polymerase delta(Polδ) and re-ligation is performed by Ligase 110,19. 
1.2.3 Mismatch Repair (MMR) 
MMR plays a major role in eukaryotic cells to correct and prevent  
mutations caused by mismatch of bases during replication of DNA2. 
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Replication errors are one of the main sources of mismatches, leading 
to the formation of insertions and deletions of nucleotides in the DNA 
sequence. Other sources include spontaneous decay of DNA due to 
base deamination, oxidation and methylation20,21. The DNA 
mismatches are repaired by a specific set of proteins: MutS Homolog 2 
(MSH2), MutS Homolog 6 (MSH6), MutS Homolog 3 (MSH3), MutL 
Homolog 1 (MLH1) and Post Meiotic Segregation increased 2 (PMS2) 
belonging to the MutS and MutL families22. MSH2 and MSH6 together 
form the MutSα complex, which repairs single base mismatches; 
MSH2 and MSH3 form the MutSβ complex that repairs longer 
mismatched nucleotides23. Exo I assists in excising the mismatched 
base on the 3’ strand with the help of MutS and MutL proteins, 
whereas for excising a mismatched base on the 5’ strand only MutS 
proteins are required. Ligase 3 and Polδ are involved in re-
synthesising the DNA and sealing the gap caused by the excision24,25. 
1.2.4 Homologous Recombination (HR) 
Homology directed repair is an error free, template dependent 
process, which helps in accurately re-synthesising the damaged DNA 
at the break site26. HR occurs in late S and G2 phases of the cell  
cycle27. In HR, the DNA with the DSB seeks an undamaged 
homologous DNA strand to use as a template molecule for repair. The 
first step of HR involves trimming back of one strand of DNA in 5’ to 3’ 
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direction by the MRE11–Rad50–NBS1 complex, leading to the 
formation of a 3’ single-stranded DNA fragment28. The Rad52 
nucleoprotein binds to this fragment and interacts with Rad51 causing 
an interchange with the undamaged DNA strand29. RPA assists Rad51 
protein in the formation of nucleoprotein filaments which adhere to 
undamaged DNA with the help of its sister proteins Rad51B, Rad51C 
and Rad51D, X-ray repair cross complementing protein2 (XRCC2) and 
X-ray repair cross complementing protein3 (XRCC3)30-32. The DNA 
strand interchange between homologous duplexes leads to the 
formation of Holliday junctions resulting in heteroduplex DNA formation 
with four junctions which migrates along the DNA and increases the 
length of the heteroduplex DNA. This phenomenon is known as branch 
migration33. The Holliday junctions are initiated by a class of enzymes 
known as the resolvases. Only two eukaryotic resolvases have been 
identified so far; Yen1 resolvase in yeast and GEN1 resolvase in 
humans34,35. After the homology search and strand invasion, the 
damaged DNA is extended by polymerases generating two intact DNA 
fragments and Ligase 1 rejoins the broken ends36,37. 
1.3 VDJ Recombination 
VDJ recombination is a critical step during B and T cell differentiation 
 
in which these cells undergo recombination to generate a wide array of 
B and T cell antigen receptors (BCR & TCR)38. In mammals there are 
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seven antigen receptor loci, which vary in configuration and the 
number of Variation (V), Diversity (D) and Joining (J) segments. A 
typical germ line antigen locus contains V, D, J segments along with a 
recombination signal sequence (RSS) made up of heptamer and 
nonamer elements. VDJ recombinase is an enzyme made up of 
recombination activating genes 1 and 2 (RAG1 & RAG2), which cleave 
at the RSS sequence causing a single strand nick between RSS 
sequence and the adjacent coding segment39. The nicking results in 
the generation of 3’ OH group, which uses another RSS sequence by 
binding to it, thereby creating a DSB. This interaction produces broken 
ends of DNA in the form of two hairpin ends and 2 blunt ends. These 
broken DNA ends, continue their linkage with RAG proteins forming 
the post cleavage complex (PCC)40. The RAG proteins are a part of 
PCC, they direct the broken ends to enter the NHEJ pathway, thereby 
producing rearranged gene segments known as coding joint and signal 
joint41. The coding joint comprises of V-DJ for heavy chains and V-J for 
light chains, whereas the signal joint consists of head to head linkage 
of RSS sequences. At times, the repair of the breaks formed  in VDJ 
recombination becomes deviant leading to formationof chromosomal 
translocations, inversions and deletions. Such consequences lead to 
genomic instability resulting in lymphoid malignancies. This feature is 
commonly observed in Leukemias. 
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1.4 DNA Ligases 
Mammalian DNA ligases belong to a family of phosphotransferase 
enzymes known nucleotidyltransferases that use adenosine 
triphosphate (ATP) as a cofactor42. They are involved in the formation 
of phosphodiester bonds between neighbouring 3’ hydroxyl  and 5’ 
phosphate groups in nicked DNA 43. All the three DNA ligase enzymes, 
Lig1, 3 and 4, share a similar catalytic core comprising of an OBD and 
AdD domains. An additional DBD boosts the activity of the catalytic 
region. The mechanism of DNA ligases functioning has been 
explained in (Fig 2). 
1.4.1 DNA Ligase1 
The human DNA LIG1 gene encodes the single Ligase 1 polypeptide. 
Ligase 1 polypeptide is made up of 919 amino acids (Fig 3). The 
structure of polypeptide is mainly composed of a non-catalytic core 
consisting of a nuclear localization signal (NLS) and replication factory 
targeting sequence (RFTS). The conserved catalytic core consists of 
the OBD, AdD and DBD domains44. The Ligase 1 enzyme is known to 
be an active participant in DNA replication 45. The catalytic core of 
Ligase 1 is involved in the ligation of DNA nicks between nearby 
Okazaki fragments (shorter DNA fragments created anew on the 
lagging strand during DNA replication), that are made up of 150-200 
nucleotides46.  One of the proteins known to interact with Ligase 1 
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Figure 2: Representation of DNA Ligase reaction mechanism. 
The catalytic region of DNA ligases consists of OB(Oligobinding domain) 
AdD(Adenylation domain) and DBD (DNA binding domain) domains.The catalytic 
regions interacts with ATP to release a pyrophosphate. When an adenylated ligase 
recognises a nick and binds to it, it undergoes a confirmational change such that all 
the ligase encircles the nick.The AMP from AdD attaches itself to the 5’ phosphate 
group of the nick. The non adenylated ligase now uses the 3’ hydroxyl group as a 
nucleophile to attack the 5’ adenylate resulting in phosphodiester bond formation and 
release of Ligase and AMP(adapted from Tomkinson AE et al., 2013)47.  
 
was proliferating cell nuclear antigen (PCNA); it is a processivity             
factor that controls the activity of polymerase delta during DNA                  
replication 48. Fibroblasts retrieved from patients with defective       
Ligase 1 activity, showed poor lagging strand synthesis 49. Further 
studies were done to check whether Ligase 1 is essential for 
maintaining cell viability. Mice lacking the Ligase 1 enzyme were 
generated using a gene-targeting method in embryonic stem cells. The 
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embryos seemed to survive well despite of absence of Ligase 1 clearly 
suggesting that another ligase is compensating for the loss 50. Ligation 
steps of both NER and BER pathways use Ligase 1 for sealing the 
DNA breaks. Ligase 1 deficiency was identified in a patient with 
 
 
 
 
Figure 3: Structure of human DNA Ligase 1 polypeptide (adapted 
from Ellenberger T et al., 2008)44.  
 
 
missense mutations in different alleles of the LIG1 gene; typical 
symptoms of this deficiency included mental retardation, poor growth, 
immunodeficiency and sensitivity to sunlight. Later, cell lines were 
developed from the patient and studies showed flaws in DNA 
replication and repair only 51,52. VDJ recombination seemed to be 
functioning normally in fibroblasts extracted from patients with ataxia 
telangiectasia and Bloom’s syndrome, thereby not explaining the 
reason for causing immunodeficiency 53. In the similar lines, mice with 
defective Ligase 1 activity were generated by creating an R771W point 
mutation, the mice had a poor growth rate along with high genomic 
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instability in spleen cells, which caused spontaneous epidermal and 
cutaneous tumours and increased cancer incidence 54. 
 
1.4.2 DNA Ligase 3 
The human LIG3 gene encodes several transcripts. Due to alternative 
splicing it gives rises to two different transcripts LIG3α and LIG3β. The 
LIG3α and LIG3β further encode two polypeptides each due to 
alternative translation. Between the two polypeptides, one has a longer 
sequence as compared to the other (Fig 4) 44. The shorter polypeptide 
is a nuclear protein. The longer polypeptide comprises of an additional 
mitochondrial leader sequence (MLS) region at the N terminal55. The 
Ligase 3α polypeptide consists of a BRCT domain where as the Ligase 
3β polypeptide has NLS 56 at the C terminal whereas the N terminal 
consists of a zinc finger and phosphorylated serine residues (Ser123 
and Ser210) (Fig 4) 57. They are comprised of a catalytic core where 
the active lysine site resides 44. Studies have shown that disruption of 
the LIG3 gene in mice resulted in halting embryonic development 
resulting in embryonic death 58. Even the expression levels of XRCC1, 
its interacting partner, were unhindered after the targeted mutation58,59. 
1.4.3  DNA Ligase 4 
 
DNA Ligase 4 is an ATP-dependent ligase, which is encoded by the 
LIG4 gene. The first human cDNA clone of the Ligase 4 enzyme was 
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cloned, sequenced and mapped from human cell nuclei 60. Studies 
suggest that the XR-1 cell line, which is deficient in XRCC4 gene 
encoding the XRCC4 nuclear phospho protein, is also negative for 
expression of Ligase 4 protein. However, the introduction of the human 
XRCC4 cDNA clone into the altered cell line leads to the positive 
expression of Ligase 4, clearly suggesting that the expression and 
function of XRCC4 and Ligase 4 enzyme are interdependent 61. 
Improper functioning of Ligase 4 due to defects in the enzyme, leads 
to malfunctioning of NHEJ pathway. This defect was identified in 
 
Figure 4 : Structure of human DNA Ligase 3 polypeptides. The 
Ligase3α (both nuclear and mitochondrial) consist of a BRCT domain 
where the ligase3β (both nuclear and mitochondrial) consist of an NLS 
domain(adapted from Ellenberger T et al., 2008) 44. 
 
certain patients who exhibited symptoms such as mental retardation, 
microcephaly, sensitivity to s, immunodeficiency and genomic 
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instability 62. Cell lines derived from these patients were extracted and 
were studied to identify mutations responsible for causing defects in 
Ligase 4 activity. A R278H mutation was identified in the Ligase 4 
enzyme, which restricts the functioning of the enzyme. A mouse model 
with this mutation showed signs of retarded growth, sensitivity of 
irradiation and faulty VDJ recombination 63. Evidence from research on 
LIG4 mutant cell lines clearly implies that cells devoid of LIG4 gene 
have low endurance levels upon irradiation making them IR sensitive, 
similar to that of XRCC4 mutant cell lines 64. LIG4 deficiency is also 
linked with embryonic death in mice as a result of the lack of 
lymphocytes due to malfunctioning of VDJ recombination 65. 
Unrepaired DNA damage in a cell leads to apoptosis via the p53 
pathway; the damage caused is recognized, resulting in the 
phosphorylated activation of p53. Once p53 is activated it follows any 
of the two pathways, one where the cell directly undergoes apoptosis 
and in the other pathway, p53 further recruits and activates 
downstream transcription factors for apoptosis 66. The Ligase 4 
enzyme requires a high-energy cofactor, like ATP, to catalyse 
phosphodiester bond formation between the broken DNA strands. The 
Ligase 4 enzyme, has a multi-domain architecture making it flexible to 
open and close around DNA. The Ligase 4 polypeptide is made up of 
911 amino acids (Fig 5). The Ligase 4 polypeptide’s catalytic core has 
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DBD and OBD domains which are active participants in adenylation of 
the enzyme. The BRCT domains in the C terminal region are 
responsible for interaction with XLF protein 67. The N terminus has 
conserved DBD and catalytic domains. 
 
Figure 5: The domain model of Ligase 4 protein (adapted from 
Ellenberger T et al., 2008)44. 
 
 
The catalytic core further comprises of an adenylation oligobinding 
domain (AdD) and the active site K213. The C terminus consists of two 
phospho protein binding BRCT domains, an OBD and a 
phosphorylated ser650 residue which helps in maintaining the stability 
of Ligase 4. 
1.5 Non Homologous End Joining (NHEJ) 
NHEJ is one of the major pathways responsible for repairing DSBs in 
multicellular eukaryotes, it is the only pathway which assists in making 
two broken ends of DNA compatible, and helps in fixing them      
together68. NHEJ occurs in the G0/G1 phases of cell cycle 69. One of 
the major disadvantages of NHEJ is that it lacks the ability to preserve 
genomic integrity as during the repair process, a few nucleotides are 
misplaced at the broken ends 70. VDJ recombination is a critical step 
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during B cell differentiation in which the immunoglobulin genes 
undergo rearrangement to generate the B cell antigen receptor        
(BCR)38. During this process, Recombination activating gene (RAG) 
proteins cause double stranded DNA breaks that are repaired through 
the NHEJ pathway.  
1.6 Other proteins involved in NHEJ pathway 
 
As well as DNA Ligase 4, there are several key players involved in the 
NHEJ pathway which play an essential part for successful completion 
of the repair process; they are Ku 70/80, DNA-dependent protein 
kinase, catalytic subunit (DNA-PKcs), Artemis, X-ray repair cross 
complementing protein (XRCC4), XRCC4 like factor (XLF) and DNA 
Polymerases. 
1.6.1 Ku70/80 
Ku is a sequence independent DNA binding protein, it is a heterodimer 
made up of two polypeptides, Ku70 and Ku80, that are abundant in 
cells 71. It is one of the first proteins to bind to the broken ends of DNA; 
it binds to 3’ and 5’ overhangs and blunt ends produced by     
irradiation72. Its typical toroidal (doughnut) shape allows double 
stranded DNA to easily slide through it (Fig 6), thereby enabling a 
strong bond with the phosphate backbone of DNA. The translocation 
of Ku protein along the DNA doesn’t require ATP 73. The two subunits 
of Ku are made of three domains: an amino-terminal von Willibrand A 
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domain (vWA), a central core domain and a carboxy-terminal region 
(CT) (Fig 7) . The CT domain of Ku70 consists of an additional SAF-
A/B, Acinus and PIAS domain (SAP), while the Ku80 has a longer CT 
domain to which the DNA-PKcs binds to 74. Both Ku70 and Ku80 are 
very similar to each other in structure comprising of the vWA and Ku 
core domains, the Ku80 polypeptide is slightly longer by 123 amino 
acids than the Ku70 polypeptide 67. 
 
Figure 6: Typical three dimesional structure reconstruction of a 
Ku70/80 heterodimer using images from electron microscopy 75. 
 
The three dimensional structure of Ku represents an asymmetric ring, 
which upon binding to DNA, resembles the bead threading model71. 
 
Figure 7: Structural representation of Ku heterodimers (adapted 
from Mahaney BL et al., 2009) 76.  
 
The presence of Ku protein enhances the ligation of incompatible ends 
via XRCC4-Ligase 4, but the additional presence of XLF along with 
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XRCC4-Ligase 4 heightens the efficiency of ligation of incompatible 
ends 77,78. 
1.6.2 DNA-PKcs 
DNA-PKcs is a polypeptide of 4128 amino acids with a molecular 
weight of 469 kDa 67. It is a serine threonine kinase which binds two 
broken ends of double stranded DNA as these act as a trigger of the 
kinase activity of DNA-PKcs79. Ku controls the stimulation of DNA-PKcs   
depending on the length of DNA, if DNA is longer than 26 bp, Ku 
activates DNA-PKcs  thereby enhancing the stability of binding. A study 
using the DNA-PKcs assay has confirmed that purified DNA-PKcs 
kinase activity is stimulated upon binding to double stranded DNA. The 
kinase activity was entirely dependent on the length of the DNA strand. 
Specifically, in the presence of long DNA, the kinase activity 
plummeted in the absence of Ku 80. DNA-PKcs can phosphorylate 
another component involved in NHEJ known as Artemis. They form a 
complex together, resulting in trimming of 3’ and 5’ overhangs and 
resolves DNA hairpins due to the strong endonuclease activity of 
Artemis 81. DNA-PKcs is activated by auto phosphorylation of the DNA-
PKcs  activation loop, and this autophosphorylation of protein kinase, on 
either side of the DNA break, results in proficient end joining 82. The 
typical structure of DNA-PKcs comprises of a focal adhesion targeting 
domain (FAT) at the C-terminus, a Phosphoinositide-kinase domain 
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(PI3K), a PI3K regulatory domain (PRD), a leucine-rich region (LRR) 
and a cluster of autophosphorylation sites (Fig 8) 67,79. It has an LRR 
region between 1502-1539 amino acids at the N terminus of the 
polypeptide. 
 
Figure 8: The structure of DNA-PKcs (adapted from Mahaney BL        
et al., 2009)76.  
 
The region between 3400-3420 amino acids in the FAT domain has a 
high affinity for Ku binding and the C terminal consists of the auto 
phosphorylation sites along with the FAT-C domain 67. 
1.6.3 Artemis 
Artemis is a DNA repair protein encoded by the artemis gene, first 
described in severe combined immunodeficiency (SCID) 83. The major 
function of artemis is its 5’ endonuclease activity, but when it forms a 
complex with DNA-PKcs, it also acquires 3’ endonuclease activity. The 
Artemis protein is made up of 692 amino acids and consists of a        
β-lactamase domain, metallo-β-lactamase-associated CPSF Artemis 
SNM1 PSO2 domain (β-CASP) and eleven DNA-PKcs 
autophosphorylation sites (Fig 9) 84,85. A H254L mutation in the β-
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lactamase domain results in radiosensitivity as observed in SCID86. 
During VDJ recombination, the RAG proteins cause double stranded 
DNA breaks, thereby generating DNA hairpins at the V, D and J 
segments67. 
 
Figure 9: The domain architecture of artemis protein (adapted from 
Mahaney BL et al., 2009)76.  
 
 
The Artemis- DNA-PKcs complex assists in repairing these hairpins. 
Absence or mutation of Artemis and DNA-PKcs leads to low levels or 
obstruction of VDJ recombination in humans resulting in lack of B and 
T lymphocytes 87. 
1.6.4 X-ray Repair Cross Complementing Protein (XRCC4) 
XRCC4 is one of the main components of the NHEJ Ligase complex 
that also comprises proteins such as Ligase 4 and XLF. The XR-1 
Chinese hamster ovary cell line is defective in DSB repair and VDJ 
recombination and was critical to identify the XRCC4 gene88. These 
defective cells were found to be sensitive to IR due to the absence of 
the XRCC4 gene. The XRCC4 protein is made up of 334 amino acids 
(Fig 10) 67. It has an N terminal globular head domain, followed by a 
long coiled tail at the C terminal. The XRCC4 protein has the ability to 
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homo-dimerize and tetramarize89. It forms a stable complex with 
Ligase 4 by physical interaction of its long helical coil to the BRCT 
domains of Ligase 4 enzyme; this interaction stimulates Ligase 4 
activity90,91. XRCC4 is involved in an adenylation reaction during the 
DNA ligation step92. 
 
Figure 10: XRCC4 domain architecture comprising of a head 
domain made up of 115 amino acids at the N terminus and the 
coiled coil at C terminus (adapted from Leber R et al., 1998)93. 
 
 
 
XRCC4 is phosphorylated in vitro at the C terminal and acts as a 
substrate of DNA-PKcs thereby linearizing DNA94. The ability of the 
XRCC4-Ligase 4 complex to bind to DNA is promoted by the Ku 
proteins95. The globular head domain of XRCC4 interacts with head 
domain of XLF to form a complex. Mutations in the XRCC4-Ligase 4 
complex cause termination of the NHEJ pathway. Absence of XRCC4 
in mice has been associated with improper embryonic development, 
which eventually leads to their death and also results in neuronal      
apoptosis96. Another study reveals that in the absence of Ligase 4 
protein, XRCC4 doesn’t migrate to the nucleus upon DNA damage. In 
this study, the nuclear and cytoplasmic fractions of the normal cells 
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and LIG4 deficient cells, were measured for XRCC4 expression. The    
cytoplasmic fraction of the Ligase 4 deficient cells showed altered 
XRCC4 expression when compared to normal cells indicating the 
importance of Ligase 4 protein in nuclear localization of XRCC4 
protein97. 
1.6.5 XRCC4 Like Factor (XLF)  
XLF was first described in patients with defective DNA repair who were 
sensitive to IR and had impaired VDJ recombination along with 
symptoms including growth retardation, microcephaly and 
immunodeficiency. It has been reported that patients with these 
symptoms were carrying a mutated XLF gene98. Due to the domain 
similarities between XRCC4 and XLF proteins; the XLF was named 
after XRCC4 protein as an “XRCC4 like factor”. XLF protein is made 
up of 299 amino acids; it consists of a head domain and a coiled coil 
loop region (Fig 11).  
 
Figure 11: Domain architecture of XLF protein (adapted from Leber 
R et al., 1998)93. 
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Analysis has shown that there are structural similarities between both 
XRCC4 and XLF proteins, such as they share similar globular head 
domains and also their long coiled coil domains93.  
Co-immunoprecipitation experiments have confirmed that XLF 
interacts with XRCC4-Ligase 4 complex both in vivo and in vitro93. 
1.6.6 DNA Polymerases 
DNA polymerases help in synthesising nucleotides and currently,      
15 proteins have been described in mammals99. DNA DSBs caused by 
IR, at times cannot be ligated directly by Ligase 4, as they need end 
trimming and resynthesising of a few nucleotides which is the 
responsibility of the DNA polymerases99. The polλ and polμ 
polymerases are commonly involved in VDJ recombination 100.                                                                                                                
Studies have shown that the polμ co-immunoprecipitates with the Ku 
heterodimer and also forms a complex with both Ku and XRCC4-
Ligase 4 proteins in the presence of DNA101. The interaction between 
the polymerase and the NHEJ factors takes place by the attachment of 
BRCT domains of polμ to that of Ku70/80 and XRCC4-Ligase 4 
complex. Whereas, the polymerases bind to the 5’ end of DNA through 
an 8 kDa domain99,102. Mice devoid of polμ were radiosensitive upon 
being subjected to IR and had stunted DSB repair capacity103. 
1.6.7 NHEJ pathway 
The first step of NHEJ involves keeping the broken strands of DNA in 
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close proximity to each other, a process known as synapsis. Reports 
suggest that DNA-PKcs might be involved in mediation of synapsis104. 
One of the earliest proteins to be recruited to the broken DNA ends is 
the Ku heterodimer. It binds to the phosphate backbone of DNA 
causing a change in the confirmation of the Ku protein72. The Ku 
heterodimer helps in further recruitment of DNA-PKcs and Artemis 
complex. The DNA-PKcs becomes an active protein kinase upon its 
contact with DNA and Artemis is responsible for this phosphorylated 
activation of DNA-PKcs87. The endonuclease activity of the Artemis- 
DNA-PKcs complex helps in trimming of the 5’ and 3’ overhangs 
thereby generating complementary ends81. The DNA polymerases 
such as polλ and polμ help in filling the gaps, this step is known as end 
processing81. After end processing, the nicks are ligated by the 
XRCC4-Ligase 4-XLF complex (Fig 12)67. 
1.6.8 NHEJ and its role in Cancer 
Several findings propose the involvement of the proteins involved in 
NHEJ in a wide variety of cancers. DNA-PKcs  is one of the most widely 
studied NHEJ proteins. DNA-PKcs activity was measured in the 
peripheral blood (PB) of untreated cancer patients and also in healthy 
volunteers. 
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Figure 12: Mechanism of DSB repair by NHEJ pathway (adapted 
from Lieber MR et al., 2010)67. 
 
 
The DNA-PKcs activity in PB from breast and cervical cancer patients 
was lower when compared to normal individuals. Cytogenetic studies 
revealed that chromosomal aberrations such as dicentric 
chromosomes and extra fragments of chromosomes increased with 
declining DNA-PKcs activity. These outcomes clearly link DNA-PKcs 
expression and activity to genomic instability and cancer105. It has 
been reported that epidermal growth factor receptor (EGFR) 
expression increase, or mutation, results in resistance to irradiation. 
EGFR expression promotes NHEJ by activating DNA-PKcs in malignant 
glioma and targeting DSB repair pathways might have better 
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therapeutic outcomes106. Studies have shown that increased NHEJ 
activity in cells to repair DSBs leads to cells becoming resistant to 
radiotherapy and chemotherapy.The NHEJ pathway is compromised 
upon continuous exposure to irradiation107. Immunohistochemical 
staining of tumour biopsies taken from cervical cancer patients at 
different stages, reveal the abundant presence of DNA-PKcs and 
Ku70/80 positive cells in tumours, which survived radiotherapy 
confirming the higher expression of these proteins in cervical cancer 
patients, due to increased NHEJ activity108. Increased DNA binding 
activity of Ku70/80 was observed in tumour biopsies of breast and 
bladder carcinomas, whereas Ku70/80 repair capacity was reported to 
decrease in metastatic tumours109. Up-regulation of Ku70/80 protein 
expression and DNA binding activity was detected in tumour samples 
from human non-melanoma skin cancers110. The expression of DNA-
PKcs and Ku70 proteins are augmented upon irradiation in oral 
squamous cell carcinoma111. DNA-PKcs and Ku70/80 mRNA and 
protein levels, were high in tumour tissues of colorectal cancer and this 
also correlated with high Sp1 expression, suggesting the presence of 
Sp1 transcription factor in the promoter regions of these proteins112. 
Ku80 (subunit of Ku heterodimer) expression was detected in adult 
lymphoblastic leukemia and chronic lymphoid malignancies. The Ku80 
expression was determined using reverse transcriptase polymerase 
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reaction where 8.8 and 6.2 mean fold increase in expression was 
observed when compared to control113. The study concludes that 
having high Ku80 expression will result in poor response to therapy in 
patients with adult lymphoblastic leukemia113. In analyses of genome 
wide association studies, Ku70/80 and LIG4 genes have been 
identified as candidate genes that predispose breast cancer. The study 
confirms that the presence of variants of Ku70/80 increase the risk of 
breast cancer, whereas variants of Ligase 4 result in a decreased risk 
of breast cancer114. As mentioned above, DNA-PKcs activity seems to 
be diminished in most of the cancers, but in lymphoid malignancies, 
the activity was higher when compared to normal individuals105. High 
grade lymphoma node samples had a greater number of cells positive 
for DNA-PKcs and Ku protein when compared to low grade lymphoma 
samples115. Patients resistant to treatment with fludarabine and 
chlorambucil had amplified DNA-PKcs  activity116. Due to the significant 
activity of DNA-PKcs in CLL, inhibitors have been designed to target 
DNA-PKcs . NU7441 is one such inhibitor with  IC50 value in the range 
of 0.17- 0.25 µM. Upon treatment with the inhibitor, CLL patients 
responded better to treatment with drugs such as fludarabine, 
chlorambucil and mitoxantrone117. All of the above evidence clearly 
suggests the delicate balance of NHEJ in several different cancers. Up 
regulation or malfunctioning of NHEJ is like a double-edged sword in 
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terms of cancer. Defects in NHEJ, such as mutations, lead to elevated 
genotoxic stress in cancer cells whereas hyper-activation results in 
improved survival of tumour cells118. Published studies suggest that 
downregulation of NHEJ in certain cancers might make the cells more 
sensitive to chemo-radiotherapy. This can be achieved by seeking 
inhibitors that target specific proteins involved in NHEJ that can be 
used as adjuncts for chemotherapy and radiotherapy118. 
1.6.9 Synthetic inhibitors of NHEJ 
The core proteins of NHEJ include Ku70/80 complex, DNA-PKcs, 
Artemis, Ligase 4/XRCC4, Polμ, and Polλ. To date most inhibitors of 
NHEJ inhibitors target DNA-PKcs. One of the first inhibitors to be 
generated was Wortamannin, a fungal metabolite, which is a non-
specific inhibitor of the PI3K family of which DNA-PKcs is a member 119. 
Wortamannin was used to sensitize different mammalian cell lines to 
radiation and interferes with the joining of DSBs via DNA-PKcs120. 
Another PI3K family inhibitor, LY294002, that is structurally different to 
wortamannin, also effectively radiosensitises cancer cells 121. NU7026 
(2-(morpholin-4-yl) –benzo [h] chomen-4-one), a novel small molecule 
inhibitor of DNA-PKcs that is more specific in abrogating the activity of 
the protein, has been tested in leukemic cell lines. Extensive studies 
have been carried out to investigate the radiosensitization of both 
quiescent and proliferating cells upon treatment with NU7026 122. More 
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recent studies have focussed on generating inhibitors of downstream 
proteins in the NHEJ cascade such as Ligase 4118. Using 
crystallography based studies to determine the structure of ligases and 
drug design technology, compounds which inhibit their binding to DNA 
have been described. The L89 compound inhibits all the three ligases 
(Ligase 1, Ligase 3 and Ligase 4) in in vitro NHEJ assays123. More 
recently, docking studies were carried out for inhibitors designed to 
target Ligase 4. This led to the identification of SCR7 as the lead 
compound for further studies. SCR7 prevents Ligase 4 protein from 
binding to DNA by competitive inhibition (Fig 13). This results in 
blocking of the NHEJ pathway causing an accumulation of unrepaired 
DSBs124. In mouse models of breast cancer, SCR7 resulted in a 
decrease of tumours when compared to untreated controls.  
In terms of B cell and T cell development, mice treated with SCR7 
showed decreased levels of VDJ recombination when compared to 
their untreated controls, thereby decreasing the lymphocyte count. 
To further explore the potential of the SCR7 inhibitor, mice models with  
Dalton’s Lymphoma were irradiated and treated with SCR7 inhibitor. 
The combination of SCR7 inhibitor and irradiation led to an improved 
shrinkage in tumour size. Furthermore, when combined with the 
chemotherapeutic drug etoposide, SCR7 led to a further reduction in 
tumour growth. Both the above experiments suggest that SCR7 
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enhances the sensitivity of cancer cells to irradiation and 
chemotherapy124.  
 
 
 
 
 
 
Figure 13: Structure showing interactions between DNA binding 
domain of Ligase 4 protein and SCR7 inhibitor. The grey cartoon 
model represents the DNA binding domain of Ligase 4, the coloured 
sticks represent SCR7 and the black dashes represent the hydrogen 
bonds between them124. 
 
1.7 Chronic Lymphocytic Leukaemia 
 
Chronic Lymphocytic Leukaemia (CLL) that is characterised by the 
amassing of mature B-lymphocytes in blood, bone marrow and 
lymphoid organs. This accumulation results in leukocytosis, 
lymphadenopathy, hepatosplenomegaly and bone marrow failure125. 
Most of the patients are asymptomatic, with the disease being 
diagnosed by increased abnormal white blood cell count. CLL can be 
distinguished from other B cell disorders due to a distinct surface 
marker (CD5+ 23+ sIg weak) expression126. CLL cases can be 
categorised based on the rearrangement of immunoglobulin heavy 
chain genes (IGHV) and can thus be classified as being either mutated 
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or unmutated127. The subsets have different clinical treatment and 
outcome. Some of the most common genetic lesions observed in CLL 
are 13q14 (mir15a and mir161), 11q23 (ataxia telangiectasia-mutated; 
ATM), trisomy 12 and 17p13 (TP53)128. The most commonly used 
clinical staging systems are Rai and Binet with risks being classified 
into low, intermediate and high129,130. Some of the prognostic factors 
which are unfavorable to CLL treatment include advancing age, stage 
(Rai III and IV or Binet C), shorter doubling time of lymphocytes and 
increased percentage of prolymphocytes131. Coming to treatment of 
CLL, there is no cure for the disease, however the most commonly 
used treatments include usage of alkylating agents and purine 
analogues which inhibit DNA transcription and synthesis. Purine 
analogues have shown to be better for treatment in terms of response 
rates and progression free survival on comparison with alkylating 
agents131,132. Fludarabine is one such purine analogue, an inhibitor of 
DNA polymerase, which is being used extensively for treating CLL. 
Immunotherapy using Rituximab, a monoclonal antibody against CD20 
protein present on the surface of B cells, in combination with 
chemotherapy is being used as front line treatment known as 
immunochemotherapy131,133. The above mentioned evidence in section 
1.6.9 suggests that some of the key components of the NHEJ pathway 
have a distinct role in different cancers.  
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1.7.1  DNA damage in CLL 
 
One of the most common features of CLL is the presence of 
chromosomal abberations. Studies have shown that there are several 
CLL driver genes with persistent mutations that are involved in cell 
cycle and DNA repair134. Two of the main kinases which help in 
recognising the DNA damage and alerting the cell for repair are the  
Ataxia Telangiectasia Mutated gene / Checkpoint Kinase 2(ATM, 
CHK2) and Ataxia Telangiectasia and Rad 3 related protein/ 
Checkpoint Kinase 1(ATR, CHK1). The ATM/CHK2 proteins are 
triggered in order to activate repair pathways for DSBs and ATR/CHK1 
proteins are triggered to activate repair pathways for bulky lesions and 
SSBs135. Upon irradiation ATM gets phosphorylated at the Serine-
1981 residue and as a result, ATR is recruited by RPA-bound single 
stranded DNA complex135. The active ATM helps in phosphorylation of 
its downstream substrate CHK2 at Threonine-68136. CHK1 is activated 
by the ATR-mediated phosphorylation of its two Serine residues 317 
and 345137. Both these kinases - ATM/CHK2 and ATR/CHK1 – 
eventually activate the Cyclin dependent Kinase 25 (Cdc25) and 
promote division of cells138. If successful DNA repair cannot be 
achieved, these pathways trigger the apoptotic cascade mediated in a 
p53-dependent manner 139. The ATM gene in CLL is mutated in 36% 
of cases resulting in patients responding poorly to chemotherapy due 
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to weakened DNA DSB repair140. The p53 mutations result in poor 
prognosis in CLL patients and more than 76% of them are missense 
mutations128. In CLL, the ATM-CHK2-p53 pathway plays a major role 
in triggering the programmed cell death, but mutations of p53 and ATM 
genes result in poor response of patients to conventional 
chemotherapy134. The ATM is largely involved in stimulation and 
increase of p53 expression thereby activating its transcriptional activity 
and triggering its downstream targets that are involved in apoptosis 
and cell cycle arrest141. CLL cases with 17p deletion are known to be 
resistant to standard chemotherapy but upon treatment with BCR 
pathway inhibitors such as the inhibitors of Bruton Tyrosine Kinase 
(BTK), these cases demonstrated significant improvement142. CLL 
patients treated with combination of Idelalisib, a PI3K inhibitor along 
with Rituximab responded better in terms of reduced lymphadenopathy 
irrespective of the high risk prognostic factors143. In similar lines, we 
set out to explore if the DNA Ligase 4 inhibitor  (SCR7) has a potential 
therapeutic role in CLL. In order to do so, we inititiated this study to 
determine the expression of DNA ligases in primary CLL samples.  
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Aims 
 
The aims of my project were: 
1) To investigate the expression of DNA Ligases in CLL: 
a) Examine the mRNA expression levels of LIG4, LIG3 and 
LIG1 in both B- cell lines and primary CLL samples. 
b) Determine the protein expression of Ligase 4 in a cohort 
of CLL cases. 
2) Observing whether the expression levels in CLL cells are 
affected by irradiation. 
3) Examining the effects of a novel Ligase 4 inhibitor, SCR7, 
on cell behaviour. 
a) Investigating if SCR7 affects cell viability both alone and 
in combination with irradiation and/or DNA damaging 
agents. 
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Chapter 2: Methods 
 
2.1 Cell culture 
2.1.1 Cell line culture and maintenance 
Cells were cultured under sterile conditions. Complete Dulbecco’s 
Modified Eagles medium (DMEM) (Sigma Aldrich, UK) was made by 
adding Fetal Calf Serum (FCS) (10 %, BioSera, UK), L-glutamine (2 
mM, Sigma Life sciences, UK) and Penicillin-Streptomycin (1000 units, 
1 mg, Sigma Life Sciences, UK). Complete Roswell Park Memorial 
Institute medium (RPMI-1640) (Sigma Life Sciences, UK) was made 
by adding 10 % Fetal Calf Serum and Penicillin-Streptomycin (as 
above).    
2.1.2 Cell thawing  
One vial of frozen cells from a -140 °C freezer was retrieved and was 
thawed in a water bath at 37 °C. The vial was quickly wiped with 
ethanol before transferring it to the laminar air flow hood. The cells 
were washed in the media by spinning them down for 5 minutes at 500 
rcf. The supernatant media containing Dimethylsulphoxide (DMSO, 
Sigma Aldrich, UK) was discarded and the cells were re-suspended in 
5 mL complete media and transferred into a T-25 cm2 culture flask and 
were grown in an incubator set at 5 % CO2 at 37 °C (humidified). 
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2.1.3 Cell line passaging 
 
Suspension cells: For sub-culturing of suspension cells, the cells 
were counted manually using a haemocytometer and trypan blue dye 
(Sigma Aldrich, UK) and the viability was measured. The required 
numbers of cells were transferred into a new culture flask and the 
volume topped up with fresh complete media and the flask was placed 
in a 5 % CO2 incubator at 37 °C (humidified).  
Adherent cells: Sub-culturing of adherent cells was performed once 
the cells were confluent enough in the flask by observing under a 
microscope. The media were removed and the cells were washed with 
phosphate buffered saline (PBS). Then the monolayer of cells was 
trypsinised using trypsin- ethylenediaminetetraacetic acid (EDTA) 
(Sigma Life Sciences, UK) for 2 to 5 minutes. The trypsin was 
neutralised by adding fresh complete media to cells. Then the cells 
were counted using a haemocytometer by staining them with Trypan 
blue dye to check cell viability and the required numbers of cells were 
transferred to a fresh flask. Complete media was then added and the 
flask was placed in a 5 % CO2 incubator at 37 °C (humidified).  
2.1.4 Cell line freezing 
Freezing media comprising of 10 % DMSO in complete media was 
prepared. The cell viability and count was determined manually using 
a haemocytometer and trypan blue. The cells were centrifuged at    
 37 
500 rcf for 5 minutes and the supernatant was removed carefully. The 
cells were resuspended in the required volume of freezing media to 
give 1 mL of cells at 1x107 viable cells. This was aliquoted into each 
cryovial and frozen at -80 °C overnight and then transferred to -140 °C 
freezer for storage.  
 
Table 1: List of cell lines used and culture method. 
 
2.2 Molecular Biology 
2.2.1 RNA extraction 
An RNeasy kit (Qiagen, UK) was used to extract RNA from cells and 
the given protocol was followed accordingly. A cell pellet containing a 
maximum of 1x107 cells was thawed on ice and to it, 600 µL of RLT 
buffer with 10 μL of β mercaptoethanol (National Diagnostics, UK) was 
transferred into a QIAshredder placed in a collection tube. The lysate 
was centrifuged for 2 minutes at 10000 x g. To the supernatant one 
volume of 70 % ethanol was added and mixed well by pipetting and 
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applied to an RNeasy mini spin column placed in a 2 mL collection 
tube (700 μL) which was centrifuged at 8000 x g for 15 seconds. The 
flow through was discarded and the step repeated for the remaining 
volume. For DNase digestion, 350 µL of RW1 buffer was added to the 
RNeasy spin column and was centrifuged for 15 seconds at 8000 x g. 
The flow through was discarded in all of the above steps. To 70 µL 
RDD buffer, 10 µL of the DNase I stock solution was added to prepare 
DNase I incubation mix. The contents were mixed gently by inverting 
the tube. In the next step, 80 µL of the DNase I incubation mix was 
added to the RNeasy spin column membrane and was incubated at 
room temperature for 15 minutes. The column was washed with 350 
µL of RW1 buffer by centrifuging for 15 seconds at 8000 x g. Later, 
500 µL of RPE buffer was added to the RNeasy spin column and was 
centrifuged for 15 seconds at 8000 x g. Again, 500 µL of RPE buffer 
was added to the RNeasy spin column and was centrifuged for 2 
minutes at 8000 x g. The flow through was discarded in the above 
steps. The RNeasy spin column was placed in an empty tube and was 
centrifuged at full speed for one minute in order to dry the membrane. 
The RNA was eluted by placing the RNeasy spin column in a new 1.5 
mL collection tube. In the column, 30 µL of nuclease free water (NFW) 
was added and centrifuged for 1 minute at  8000 x g. The 
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concentration of RNA was measured using a NanoDrop machine 
(Thermo Scientific NanoDrop 2000, USA).  
2.2.2 cDNA synthesis protocol 
 
For generating cDNA in a single reaction in the first step, 1 µg of RNA 
was taken, to which 1 µL of Oligo(dT)12-18 Primer (Life Technologies, 
UK), 1 µL 10 mM dNTP Mix (Life Technologies, UK) were added along 
with NFW to make up to a final volume of 12 µL in an RNase free tube. 
All volumes that are described are for one reaction. The contents of 
the tube were mixed well by pipetting and were placed on a heat block 
at 65 °C for 5 minutes. Next, 2 µL of 0.1 M Dithiothreitol (DTT) (Life 
Technologies, UK) and 4 µL of 5x First-Strand Buffer (Life 
Technologies, UK) were added to the tubes and were mixed 
thoroughly and heated at 42 °C for 2 minutes. Lastly 1 µL of 
SuperScript II Reverse Transcriptase enzyme (Life Technologies, UK) 
was added to the reaction and the tubes were heated at 42 °C for 50 
minutes and then at 72 °C for 15 minutes. To prepare a negative 
control, 1 µL of NFW was used in place of 1 µL SuperScript II Reverse 
Transcriptase enzyme. The cDNA synthesised was stored at -20 °C.  
2.2.3 Polymerase chain reaction (PCR) 
 
For a single 25 µL reaction in a 0.5 µL PCR tube, 22 µL of Platinum® 
PCR SuperMix High Fidelity (Life Technologies, UK), 1 µL of forward 
primer and 1 µL of reverse primer (stock concentration 100 µM, 
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working concentration 2.5 µM, final concentration 0.1 µM) were mixed . 
For multiple reactions, a master mix was made. To the relevant tubes, 
1 µL of cDNA template was added. A negative control was set up 
using the above reagents and 1 µL of NFW, in place of the cDNA 
template. All the tubes were centrifuged briefly and placed in the 
thermo cycler. The following thermal profile was used:                         
95 °C 10 minutes (x1) 
95 °C 20 sec, annealing temperature15 sec, 72 °C 30 sec (x34) 
72 °C 10 minutes (x1) 
Hold at 4 °C 
2.2.4 Agarose gel electrophoresis  
 
The amplified PCR product was analysed by running it on an agarose 
gel containing ethidium bromide (EtBr, Promega, UK). Agarose (Web 
Scientific, UK) was measured using a weighing balance and 2 g was 
added to 100 mL of 1X Tris-Borate-EDTA buffer (TBE), (Sigma 
Aldrich, UK) and heated in a microwave until the agarose was 
dissolved completely. The melted agarose solution was allowed to cool 
at room temperature after which 8 µL of EtBr was added to it and 
mixed slowly. The solution was poured into a gel casting tray, pre-fixed 
with a comb, and the contents were allowed to solidify. The gel was 
transferred into an electrophoresis tank containing 1X TBE buffer. To 
the PCR products, 6X loading buffer (10 mM Tris-HCl, pH 8.0), (Fisher 
 41 
Scientific, UK), 50 mM EDTA, 15 % Ficoll-400, 0.5 % Orange G, 
(Sigma Aldrich, UK) was added and then loaded onto the gel along 
with a DNA ladder. The electrophoresis chamber was closed and the 
gel was run at 100 V for 45 minutes. After running, the gel was 
visualised was to verify the PCR products using a UV trans illuminator 
(UVITEC, UK). 
2.3 Protein analysis 
2.3.1 Cell lysis and protein determination 
 
Whole cell lysates were prepared from 1x107 viable cells. Cells were 
counted manually using a haemocytometer and Trypan Blue dye. The 
required number of cells were pelleted at 500 x g and washed with ice 
cold PBS. The supernatant was aspirated completely. To the pellet of 
cells, 200 µL of clear lysis buffer (1 % SDS, 50 mM Tris, pH 6.8, 5 mM 
EDTA and 10 % Glycerol, (Fisher Scientific, UK)) was added along 
with 2 µL of complete protease inhibitor cocktail (Calbiochem, UK) and 
incubated on ice for 30 minutes. The whole cell lysate was sonicated 
on ice and clarified for 10 minutes, maximum speed of 10000 x  g, at   
4 °C. The supernatant was transferred to fresh tubes and stored at      
-20 °C until ready for use. The protein concentration of the lysates was 
measured using the Bio-Rad DC Protein Assay kit. A sufficient volume 
of Reagent A was prepared using 20 μL of Reagent S added to 1 mL 
of Reagent A. Protein standards from 0.5 mg/mL to 3 mg/mL protein 
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were prepared using bovine serum albumin (BSA) prepared in the 
same lysis buffer as the sample. To a 96 well plate, 5 μL of standard or 
sample were pipetted. To each of the wells, 25 μL of the Reagent A’ 
was added, followed by pipetting of 200 μL of Reagent B into each 
well. The plate was gently agitated to mix the reagents and incubated 
at room temperature. After 15 minutes, the absorbance of the samples 
was read at 750 nm using an FLx800 fluorescence microplate reader 
(BioTeK, USA).  
2.3.2 Western blotting 
 
To analyse protein expression, 10 % resolving and 4 % stacking gels 
were prepared. The resolving gel was made using 7.05 mL distilled 
water, 4.25 mL of resolving buffer (Geneflow, UK), 5.7 mL of 
acrylamide (Sigma Aldrich, UK), 50 µL of 10 % ammonium per 
sulphate (APS) and 15 µL of N, N, N’, N’ Tetramethylethylenediamine 
(TEMED, Sigma-Aldrich, UK). After the resolving gel was solidified, 
stacking gel was made using 4.6 mL distilled water, 1.9 mL stacking 
buffer (Geneflow, UK), 1 mL of acrylamide, 50 µL of 10 % APS and   
15 µL of TEMED. Ten micrograms of whole cell lysate was diluted in 
4x sample loading buffer (8 % SDS, 40 % glycerol, 20 % β-
mercaptoethanol, 0.008 % bromophenol blue (Sigma Aldrich, UK) and 
250 mM Tris (pH 6.8)) and boiled at 95 °C for 5 minutes. The prepared 
samples were loaded onto the gel along with a suitable molecular 
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weight marker. The gel was run at 30 mA for 60 minutes in an 
electrophoresis chamber filled with 1X running buffer (25 mM Tris, 190 
mM glycine (Fisher scientific, UK), and 0.1 % SDS). The proteins were 
transferred from the polyacrylamide gel to a Polyvinylidene fluoride 
(PVDF) membrane (Roche, UK) using a wet transfer system. The 
membrane was pre-soaked in methanol and was sandwiched between 
sponges pre-soaked in 1X transfer buffer (25 mM Tris, 190 mM 
glycine), and filter paper. The enclosed sandwich was placed in the 
tank containing 1X transfer buffer. The transfer was performed at 75 V 
for 60 minutes. After transfer, the membrane was blocked using non-
fat milk powder (3 %) dissolved in 1X TBS-Tween 20 (0.05%) solution 
for 60 minutes at room temperature with agitation. Following blocking, 
the membrane was incubated with the chosen primary antibody (Table 
2), diluted to the required concentration, in blocking solution. The 
membrane was incubated with the antibody overnight at 4 °C with 
agitation. Following incubation, the membrane was washed thrice at 5 
minute intervals with 1X PBS-Tween 20 (0.05 %) solution. After the 
washes, the membrane was incubated with desired secondary 
antibody diluted 1:5000 with blocking solution at room temperature for 
60 minutes, with agitation. After incubation, the membrane was 
washed as described above. The protein bands were detected using 
ECL (Immobilon western chemiluminiscent HRP substrate Millipore, 
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USA) or ECL advanced kits (Westar Supernova, Gene flow, UK) and 
digital images were captured using a luminescent image analyzer 
(FUJIFIL LAS1000, Japan). 
 
Table 2: The above table comprises of the list of antibodies and 
their respective final dilutions used for studying protein 
expression. 
 
 
2.4 Measurement of cell proliferation using a colorimetric BrdU 
ELISA assay 
 
The assay is based on the incorporation of the pyrimidine analogue 5-
Bromo-2’-deoxyuridine (BrdU) into the genomic DNA of replicating 
cells. Different cell lines (Daudi, HeLa and MEC1) were cultured and 
treated with varied concentrations of SCR7 inhibitor (Kind gift from Dr. 
Sathees Raghavan) (10 µM, 50 µM, 100 µM, 250 µM) alone and in 
combination with irradiation (5 Gy). Approximately 1 x 104 cells were 
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seeded in each well of a 96 well plate in triplicate according to their 
treatments, in a final volume of 100 µL. To each of the wells 10 µL of 
BrdU (10 µM stock concentration, final concentration 1 µM) labelling 
solution was added (now labelling medium) and incubated at 37 °C for 
2 hours before the completion of time points. The labelling medium 
was removed carefully (plates containing suspension cells were first 
centrifuged at 300 x g for 10 minutes) using a pipette. Once the 
labelling media was removed, the cells were subjected to drying at 60 
°C for 1 hour. After the cells were dried, 200 µL FixDenat solution 
(Roche, UK) was added to each of the wells and the plates incubated 
for 30 minutes at room temperature. The FixDenat solution was 
removed by flicking the plate and tapping on absorbent paper. For one 
96-well plate, dilute 100µL Anti-BrdU-POD stock solution in 10 mL 
antibody dilution solution. One hundred microlitres of anti-BrdU-POD 
working solution was added to each of the wells and the plate 
incubated for 90 minutes at room temperature. The anti-BrdU-POD 
working solution was removed by flicking the plate and the wells 
washed three times using 200 µL of washing solution (Roche, UK). 
The washing solution was removed by flicking the plate and 100 µL 
substrate solution (Roche, UK) added to each of the wells. The 
solution was left in the well until a colour change was observed across 
the wells (approximately 5-30 minutes). Once the colour development 
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was sufficient for measurement, the reaction was stopped by the 
addition of 25 µL 1 M sulphuric acid to each well. The plate was placed 
on a shaker for 1 minute in order to mix the contents thoroughly and 
the absorbance was measured within 5 minutes using an ELISA 
reader (FLX800 microplate reader; BioTeK, USA) at 450 nm. 
 
2.5 Measuring apoptosis of cells by flow cytometry using PI and 
DiOC6   
 
Daudi, MEC1 and HeLa cells were used to perform apoptosis assays. 
One hundred microlitres of cell suspension (1x104 viable cells) was 
taken into a polypropylene tube (Beckman Coulter, Epics XL MCL, 
UK). Propidium Iodide (PI) (100 mg/mL; Sigma, UK) and 3,3'-
dihexyloxacarbocyanine iodide (DiOC6) (60 mM; Molecular Probes, 
UK) were diluted in PBS to concentrations of 2 mg/mL and 40 mM 
respectively. To each of the cell samples, the diluted DiOC6 was 
added such that the final concentration was 40 nM and the samples 
were incubated in the dark at 37 °C for 20 minutes. Following this, the 
diluted PI solution was added to the samples such that the final 
concentration was 1 µg/mL. The sample and dye were mixed gently 
and were placed in the incubator at 37 °C, 5 % CO2 for 5 minutes. The 
samples were then analysed by flow cytometery (FACScalibur, 
Beckman Coulter, UK). 
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2.5.1 Measuring apoptosis of cells upon treatment with 
irradiation only 
 
HeLa and MEC1 cells were seeded in 24 well plates at a density of 5 x 
104 cells/well. The following morning, cells were treated with irradiation 
(3 Gy or 5 Gy) and returned to the 5 % CO2 incubator at 37 °C. 
Apoptosis was measured, following the method described in section 
2.5 after 24, 48 and 72 hours. 
2.5.2 Measuring cytotoxicity and radiosensitivity of cells upon 
treatment with different concentrations of SCR7 inhibitor 
and irradiation 
 
For the cytotoxicity and radiosensitivity experiments, Daudi and MEC1 
cells were seeded in 24 well plates at a density of 5 x 104 cells/well. 
The SCR7 inhibitor was diluted with DMSO therefore, negative 
controls where prepared for both experiments with 0.1% DMSO and 
untreated cell lines also included. To determine the cytotoxicity, after 
the cells were seeded the previous day, they were treated with 5 Gy 
irradiation by placing the cells in a tube and they were replaced into 
the plate, and then incubated in the presence of the SCR7 inhibitor at 
10 µM, 50 µM, 100 µM, and 250 µM. As the inhibitor was dissolved in 
DMSO, a negative control consisting of 0.1% DMSO only was also 
included. An untreated sample of each cell line was also included. The 
cells were harvested at 24 hours and 48 hours and apoptosis was 
measured by following the method in section 2.5. To determine the 
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radiosensitivity following the seeding of Daudi and MEC1 cells the 
previous day in 24 well plates at a density of 5 x 104 cells/well they 
were treated with varied concentrations of SCR7 inhibitor (10 µM, 50 
µM, 100 µM, and 250 µM). After 24 hours the cells were exposed to 5 
Gy irradiation and were replaced in the 5% CO2 incubator at 37 °C. 
The SCR7 inhibitor was diluted using DMSO. Negative controls 
consisting of 0.1% DMSO only and untreated samples without inhibitor 
and irradiation were also included. For both the experiments, the cells 
were harvested at 24 and 48 hours following irradiation treatment to 
study cell death by following the method in section 2.5. 
 
 
2.6 Statistical analysis 
 
The data was analysed to measure statistical significance using Two 
way ANOVA for data generated for MEC1 cells by cytotoxicity assay 
and Daudi cells by BrdU assay. Prism 5 software and microsoft excel 
were used to carry out these tests. 
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Chapter 3: Results 
 
3.1 Verifying cDNA quality using GAPDH primers 
 
The cDNA synthesised from a variety of cell lines (MEC1, PC3, 
22RV1, H417, K562, HUT78, HeLa and Daudi) was verified for  quality 
by PCR using GAPDH primers (Table 3). PCR products were 
analysed by agarose gel electrophoresis as described in Chapter 2 
and results shown in (Figs 14 a and b).  
 
 
Figure 14: Verifying cDNA quality using GAPDH primers              
PCR amplification of cDNA (from MEC1, 22RV1, PC3 and H417 cell lines) using 
GAPDH primers was performed and the reactions were analysed by agarose gel 
electrophoresis.(a) Lanes 1, 2 and 3 show the amplification of MEC1 cDNA from a 
single aliquot. Lanes 5, 6 and 7 are amplifications of 3 independent MEC1 cDNA 
samples. Lanes 9, 10 and 11 are amplified products of cDNAs prepared from 22RV1, 
PC3 and H417 cells. Lane M: 100 bp DNA ladder (New England Biosciences, UK). 
(b) PCR amplification of GAPDH primers using cDNA from Daudi, HeLa, K562, 
MEC1 and HUT78 cDNA’s. 
 
Successful amplification, indicated by the presence of a single band at 
450 bp, was detected from amplifications of all independent aliquots of 
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MEC1 22RV1, H417, K562, Daudi, HeLa, HUT78 and K562 cDNAs 
(Figs 14 a-b), but not PC3 cDNA (Fig 14a, lane 10) which was likely 
due to failure of cDNA synthesis. Having confirmed the cDNA quality 
obtained from MEC1, 22RV1, H417, K562, Daudi, HeLa, HUT78, 
these were used for further experiments. 
3.2 Optimisation of annealing temperature of primers specific 
for DNA ligases 
 
Several different primer sets were designed (Table 3) to examine the 
expression of LIG1, LIG3 and LIG4 mRNA. Gradient PCRs were 
performed where the PCR reaction mixtures were subjected to a range 
of temperatures (52 °C to 65 °C) to ascertain the optimal annealing of 
the primer sets. K562 and MEC1 cDNA were used as templates for 
analysis. Representative gel images are shown below in (Fig 15a, b, c 
and d). Two independent sets of primers for the LIG1 gene were 
designed to generate amplicons of 148 bp and 110 bp respectively. 
Though amplification was observed at 52 °C, 53.7 °C and 56.3 °C for 
both the primer sets, several non-specific bands (representative non-
specific bands are highlighted in red) were detected above the 
appropriate amplicon (Fig 15a and b). At 58 °C non-specific bands are 
seen along with required amplification (Fig 15b) for both sets of LIG1 
primers and at higher temperatures such as 60.5 °C and 62 °C, the 
intensity of amplification decreased (Fig 15b and c). 
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Figure 15: Gradient PCR of primer sets to determine optimal 
annealing temperature(a, b & c). Gradient PCR was performed to determine 
the optimal annealing temperatures of LIG1 primer (sets 1 and 2), LIG 3 primer (sets 
1 and 2) and LIG4 primers (sets 1, 2 and 3). K562 cDNA was used as the template. 
The temperature ranges from 52 °C to 62 °C are shown.The sizes of amplicons for 
LIG1 sets 1 and 2 are 148bp and 110bp, LIG3 sets 1 and 2 are 150bp and 136bp 
and lastly for the three sets of LIG4 are 136bp,90bp and 100bp. The negative 
controls of the PCR reaction for all the primer sets were run at 52 °C with water. 
Highlighted red boxes indicate non-specific bands. (d) Gradient PCR using LIG4 set 
4 primer set and LIG1 primer set 1, with MEC1 cDNA and K562 cDNA as templates, 
were performed to identify ideal annealing temperatures.The expected amplicon 
sizes for LIG4 set 4 in lanes 1 to 6 are 154bp and LIG1 set1 primers in lanes 8 to 13 
are 148 bp respectively. Lanes 7 and 14 are the negative controls for the PCR 
reaction. The primer sets have been mentioned in detail in Table 3. 
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Similarly for the both the LIG3 primer sets the appropriate amplicons 
were detected at 150 bp and 136 bp respectively (Fig 15a and b). 
The bands were detected consistently throughout the temperature 
gradient, but high intensity amplified bands were detected at 58 °C 
suggesting that this was the ideal annealing temperature (Fig 15b). 
Lastly, the three sets of LIG4 primers were designed to generate     
136 bp, 90 bp and 100 bp amplicons. LIG4 set 1 primers showed a 
non-specific band (Fig 15a and b) and LIG4 set 2 primer set displayed 
faint amplification consistently across the whole temperature gradient 
(Fig 15a and b). Only LIG4 primer set 3 generated a single strong 
band throughout the temperature gradient (Fig 15a and b). Due to 
contamination problems with PCR, an additional  primer set was 
designed for LIG4 gene, which amplified a 154 bp region of the cDNA. 
The intensity of amplification was consistent along the temperature 
gradient from 55 °C to 64.8 °C (Fig 15d) in lanes (1 to 6).  
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Table 3: Characteristics of primers used for PCR amplification of 
LIG1, 3 and 4 genes along with GAPDH primers as seen in 
Figures 14 and 15. 
 
                                                                              
       
Table 4 : The list of primers used in the next set of 
experiments(Figure 16 and 17). 
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3.3 Determination of the expression of LIG4, LIG3 and LIG1 
mRNA in CLL samples and the human bone marrow stromal 
cell line (HS-5) 
 
Each of the chosen primer sets were used to amplify specific DNA 
ligases from cDNA synthesised from primary CLL patient samples  and 
additionally from the HS-5 cell line. Upon PCR amplification using the 
LIG4 primer set 4, specific product was observed in all the cases (Fig 
16). Amplification from the HS-5 cell line cDNA was less robust. 
                                                                                                        
Figure 16: End point PCR using LIG4 primer set 4 and cDNA 
extracted from primary CLL patient samples. The expected 154 bp 
amplified product is seen in all CLL cases the negative control with water was clear.  
 
                                                                                                           
 
Figure 17: Endpoint PCR of LIG3 and LIG1 using described 
primer sets with cDNA extracted from CLL patient samples.        
The expected amplicon sizes for both primer sets (LIG3 set 3 and LIG1 set 3) are 
148 bp. Three different CLL cases along with HS-5 cell line cDNA were used in the 
PCR reaction.                                                               
                                                                                                       
Further PCR amplification was carried out using LIG3 and LIG1 primer  
sets and cDNA generated from 3 CLL patient samples and HS-5 cell 
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line. Robust amplification was observed in all the cDNA samples 
including HS-5 cell line for both the primer sets as seen in (Fig 17). 
3.4 Analysis of DNA Ligase 4 protein expression in 
haematopoietic cell lines  
 
In order to establish the conditions, examine the specificity of a 
commercial antibody to detect Ligase 4 (Polyclonal Antibody, Protein 
tech, UK) and determine the protein expression whole cell lysates 
were prepared from cell lines a panel of in house cell lines (Daudi, 
HeLa, K562, MEC1, HUT78, RHUT78 and RMEC1) from protein 
analysis as described in the methods section. Two different protein 
concentrations were used (10 and 20 µg).  
              
                    
Figure 18: Western blot depicting Ligase 4 protein expression in a 
panel of lymphoid cell lines using a commercial polyclonal 
antibody. Whole cell lysates of Daudi, HeLa, K562, MEC1 and HUT78 cells were 
prepared and 10 µg and 20 µg of protein was loaded onto polyacrylamide gels. After 
transfer, the PVDF membrane was probed with a Ligase 4 polyclonal antibody 
(Protein tech, UK; 1:500 dilution). HeLa lysate served as positive control. The  
expected protein size is 100-104 kDa. The bands appearing around 75 kDa could be 
non-specific. Equal amount of protein was loaded on to the gel as determined by Bio-
Rad DC Protein Assay kit. 
 
HeLa cell lysate served as the positive control and Ligase 4 protein 
expression was readily detected  (Fig 18). The appearance of a 
second band at 75 kDa in the Ligase 4 blots prompted us to validate 
this further. Therefore, an alternate antibody (Anti-DNA Ligase IV 
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antibody, Abcam, UK) was obtained. The latter antibody did detect a 
single and strong band in HeLa cell lysates but only faint bands in 
K562, MEC1 and RMEC1 cell lines (Fig 19). 
                   
 
Figure 19: Western blot analysis of DNA Ligase 4 protein 
expression in cell lines using an Anti-DNA Ligase IV antibody 
(Abcam, UK). 10 µg of whole cell  protein lysates from Daudi, HeLa, K562, MEC1 
and RMEC1 were loaded onto a gel and the proteins transferred onto a PVDF 
membrane and probed with Ligase 4 antibody (1:1600). The expected protein size 
109 kDa. A frozen lysate of MEC1 cell line was also used (MEC1old). Equal amount 
of protein was loaded on to the gel as determined by Bio-Rad DC Protein Assay kit. 
 
 
 
In parallel, additional experiments were sought to investigate protein 
expression of DNA Ligase 4 in MEC1 and HUT78 cell lines along with 
their counterparts that are resistant to Romidepsin, a histone 
deacetylase inhibitor (HDACI). Romidepsin is licensed for the 
treatment of cutaneous T cell lymphoma144. Previous studies have 
identified HDACIs as potential DNA damaging agents and suggested 
that treatment of cells with HDACIs resulted in activation of NHEJ and 
HR145. HDACIs have been reported to increase NHEJ frequency  due 
to generation of DSBs. However, upon prolonged exposure, several 
human cell lines have been reported to acquire resistance to these 
inhibitors, most likley due to HR 145. As XRCC4 is another downstream 
NHEJ protein which is a key partner of DNA ligase 4 in the DNA 
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ligation reaction, it’s expression was also investigated in these 
resistant cell lines. Although Ligase 4 protein clearly expressed in 
HeLa cell lysates, parental MEC1 and HUT78 cells  showed only weak 
expression.  There was a hint of upregulation of DNA ligase 4 
expression in the resistant RHUT78 and RMEC1 lines but was not a 
consistent finding in repeat experiments (Fig 20a). The expression of 
XRCC4 protein, in contrast was robust in all the cell lines (Fig 20b).  
                     
 
Figure 20: Western blot analysis of downstream NHEJ proteins in 
a variety of cell lines. 10 µg of protein from HeLa, (parental) HUT78, MEC1, 
and (resistant) RHUT78 and RMEC1 whole cell lysates was loaded on to the gel and 
after transferring the proteins onto a PVDF membrane, was probed with a). Ligase 4 
(1:1600) and b) XRCC4 (1:2000) antibodies. Expected protein sizes for both the 
antibodies are Ligase 4: 109 kDa and XRCC4: 50 kDa. The bands appearing around 
75 kDa for Ligase 4 could be non-specific.Equal amount of protein was loaded on to 
the gel as determined by Bio-Rad DC Protein Assay kit. 
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3.5 Analysis of the expression of Ligase 4 and XRCC4 proteins 
in CLL patient samples 
 
A random cohort of CLL cases were chosen to investigate the 
expression of Ligase 4 and XRCC4 proteins by immunoblotting. The 
expression of Ligase 4 was variable in this cohort and was  
                     
Figure 21: Verifying the protein expression of Ligase 4 and 
XRCC4 in CLL cases. 10 μg whole cell lysate from CLL cells were loaded on to 
a gel and the proteins transferred onto a PVDF membrane. The membrane was 
probed with Ligase 4 antibody (1:1600 dil), expected protein size 109 kDa, XRCC4 
antibody (1:2000 dil), expected protein size 50 kDa. The blot was later probed with 
beta actin antibody (1:10000 dil), which was used as a loading control. 
 
 
detected only in a subset of cases 2932, 2860,1687,1786, 1692 and 
2283 (Fig 21). The cases 2932 and 2860 had a genetic abnormality in 
the form of a deletion 11q22. In contrast, XRCC4 expression was 
detected more widely across all the CLL cases. 
 
3.6 Analysis of the effects of irradiation on expression of  
Ligase 4, XRCC4 and p53 proteins 
 
In order to understand the effects of irradiation on the expression of  
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Ligase 4, XRCC4 and p53, MEC1 and HeLa cell lines were chosen as 
both show good expression of wild type p53 146. HeLa cells served as 
a positive control for Ligase 4 expression. The cell lines were cultured 
and exposed to two different doses of irradiation, 3 Gy and 5 Gy. Cells 
were harvested at 3, 6 and 24 hours and cell lysates prepared. 
Immunoblotting was carried out to determine the expression of the 
above mentioned proteins. In the MEC1 cell line, there was no 
significant change in expression of Ligase 4 protein upon exposure to 
the two different grades of irradiation when compared to untreated 
controls at the different time points. In contrast, in the HeLa cell line, 
Ligase 4 expression was comparitively more prominent than in 
untreated controls at both grades of irradiation and time points (Fig 
22a). There was less variability in XRCC4 protein expression in both 
irradiated and untreated lysates upto 24 hours in both MEC1 and HeLa 
cell lines (Fig 22b). The expression of p53 expression, which was 
used as a positive control as it is reported to be higher in irradiated 
samples was detected strongly across all MEC1 lysates but not in the 
HeLa lysates. Only faint bands were visualised in HeLa cells and be a 
reflection of the batch of HeLa cells used147. The experiment was 
repeated to study the effects of longer incubation times after irradiation 
to see if the expression of Ligase 4 protein was altered (see Fig 23).  
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Figure 22(a, b and c): Effect of IR (3 Gy and 5 Gy) after 3, 6 and 24 
hours on DNA Ligase 4, XRCC4 and p53 expression in HeLa and 
MEC1 cells. 10 µg of protein generated from irradiated HeLa and MEC1 cells 
harvested at different time points (3, 6 and 24 hours), were loaded on to a gel and 
after transferring the proteins onto a PVDF membrane, the membrane was probed 
with a) Ligase 4 antibody (1:1600), b) XRCC4 antibody (1:2000), and c) p53 
antibody (1:1000). The blot was later probed with beta actin antibody.  
 
 
 
The Ligase 4 protein expression in MEC1 cells  treated with both 3 Gy 
 
and 5 Gy at 48 hours, was higher when compared to untreated control 
(Fig 23a). Changes in Ligase 4 expression in HeLa cells on irradiation 
were less prominent at all time points (Fig 23a). There was less 
variability in XRCC4 protein expression in both treated and untreated 
samples across all the three time points (Fig 23b).  
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Figure 23 (a, b and c): Effect of IR (3 Gy and 5 Gy) after 24, 48 and 
72 hours on DNA Ligase 4, XRCC4 and p53 expression in HeLa 
and MEC1 cells. 10 µg of protein generated from irradiated HeLa and MEC1 
cells harvested at different time points (24, 48 and 72 hours) were loaded on to a gel 
and after transferring the proteins onto a PVDF membranes, probed with a) Ligase 4 
antibody (1:1600 dil, 109 kDa), b) XRCC4 antibody (1:2000 dil, 50 kDa) (23b) and c) 
p53 antibody (1:1000 dil), 53 kDa). The blot was later probed with beta actin antibody 
(1:10000dil). 
 
 
Expression of p53 protein seemed to be slightly higher in irradiated 
 
MEC1 cells at 48 hours and 72 hours with a dose of 5 Gy irradiation 
compared to the non-irradiated controls (Fig 23c). There were no clear 
changes in p53 expression in MEC1 cells (Fig 23c).   
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3.7 Analysis of the effects of irradiation and SCR7 on growth 
and survival in haematopoietic cell lines 
 
For these studies, MEC1 and Daudi cells were treated with 5 Gy of 
irradiation and additionally exposed to the DNA ligase 4 inhibitor, 
SCR7, at defined concentrations of the drug as previously           
described124. Cytotoxicity was measured using a PI and DiOC6 assay 
by flow cytometry and the percentage of live cells was calculated at 
different time intervals (24, 48 and 72 hours). As shown for Daudi cells 
(Fig 24), upon irradiation alone, the percentage of live cells dropped 
by 15.13 % at 24 hours, 30.15 % at 48 hours and 30.47 % at 72 hours 
(data described in appendix). Treatment with SCR7 alone at 
concentrations up to 100 µM, had no significant effect on cell viability. 
Upon exposure to a 250 µM of the drug, the percentage of live cells 
decreased  by 32.88 % at 72 hours. In contrast, upon the combined 
treatment with irradiation and drug, there was a decrease in the 
percentage of live cells for all concentrations when compared to 
untreated control. At 24 hours for 10 µM, 50 µM and 100 µM inhibitor 
concentrations, there was slight decrease in the percentage of live 
cells by 15.69 %, 16.14 % and 18.79 % in cells treated with 
combination of irradiation and drug when compared to treatment with 
drug alone. For cells treated with irradiation and SCR7 inhibitor (50 µM 
and 100 µM), at 72 hours the percentage of live cells dropped by  
27.55 % and 39.17 % when compared to cells treated with the inhibitor 
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only. Lastly, at 250 µM concentration, there was a narrow difference in 
percentage of live cells between cells treated with drug alone and in 
combination with drug and irradiation by 3.76 %, 18.82 % and 11.81 %  
at 24 hours, 48 hours and 72 hours respectively. In summary, only 
high concentrations of inhibitor had a significant effect on cell viability.  
      
Figure 24: Assessment of cytoxicity in Daudi cells on treatment 
with irradition and/or SCR7. Bar graphs showing the percentage of live 
Daudi cells after treatment with 5 Gy irradiation (IR) followed by treating with varied 
concentrations (10 µM, 50 µM, 100 µM, 250 µM) of the LIG4 inhibitor SCR7. The 
percentages of live cells were measured at 24 hours, 48 hours and 72 hours 
respectively. Error bars represent standard deviation from three independent 
experiments.  
 
In addition to the above experiments on Daudi cells, MEC1 cells were 
also investigated for the effects of irradiation and SCR7. There was no 
change in cell viability at all time points upon treatment with drug alone 
(10 µM, 50 µM and 100 µM) as shown in (Fig 25).  
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Table 5: Percentage of dead cells in MEC1 and Daudi cell lines 
under various treatment conditions with SCR7 and 5 Gy IR. 
 
                                
 
 
Figure 25: Assessment of cytotoxicity in MEC1 cells following 
exposure to irradiation and/or SCR7. Bargraphs showing the percentage 
of live MEC1 cells upon treatment with 5 Gy irradiation (IR) followed by treating with 
varied concentrations (10 µM, 50 µM, 100 µM, 250 µM) of LIG4 inhibitor SCR7. The 
percentage of live cells were measured at different time points 24, 48 and 72 hours 
using flow cytometric assessment of PI and DiOC6 staining. Statistical analysis was 
performed using Two way anova,  P value > 0.05. Error bars represent standard 
deviation from three independent experiments.  
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The percentage of cell death increased  upon treatment with 250 µM of 
inhibitor alone and in combination with irradiation by  34.02 %,19.22 % 
(inhibitor only) and 28.21 %, 35 % (inhibitor with IR) at 24 hours and 
48 hours respectively. The percentage of live cells at 250 µM 
decreased  by 63.73 % and 70.69 % for both the samples treated with 
inhibitor alone and in combination with irradiation at 72 hours. The 
percentage of cell death in MEC1 is visibly higher at 72 hours  for all 
combinations of drug and irradiation when compared to that of Daudi 
cells as shown in (Table 5). 
3.8 Analysis of the sensitivity of leukemic cells to irradiation 
following pre-treatment with SCR7 inhibitor 
 
To assess the radiosensitivity of Daudi and MEC1 cells, two 
concentrations of  SCR7 (10 µM and 100 µM) were used prior to 
irradiation. After 24 hours of treatment, the cells were exposed to 5 Gy 
irradiation and were harvested at 48 hours and 72 hours and the 
percentage of live cells was determined using flow cytometry. The 
percentage of live cells in treated samples  was compared to untreated 
control samples (i.e no irradiation or drug). The percentage of live 
Daudi cells did not vary for 10 µM concentration of drug alone  at both 
48 and 72 hours whereas it decreased by  6.9 % and 4.4 % for 100 µM 
concentration at 48 and 72 hours. The percentage of cell death in 
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Daudi cells at 48 hours after treatment with irradiation was 19.7 %, 
19.3 % (10 µM and 100 µM)  and 19.5 %, 17.2 % (10 µM and 100 µM) 
at 72 hours on comparison with untreated control samples (Fig 26). 
The cell death percentage pattern seems to be quite similar for both 
concentrations and timepoints suggesting that the cells were not 
sensitized to irradiation at these concentrations of the inhibitor 
treatment. Similar to Daudi cells, there was no noticeable change in  
decrease of percentage of live cells at both concentrations (10 µM  
and 100 µM) and time points upon treatment with inhibitor alone when 
compared to untreated control in MEC1 cells.  
 
                                                                                                            
Figure 26: Assessment of radiosensitivity assay of Daudi cells on 
pre-treatment with SCR7. Bargraphs showing the percentage of live Daudi 
cells upon pre-treatment with varied concentrations (10 µM and 100 µM) of LIG4 
inhibitor SCR7 for 24 hours followed by 5 Gy irradiation to measure the sensitivity of 
cells to irradiation. The percentages of live cells was measured at 48 and 72 hours 
using staining with PI and DiOC6 and flow cytometry. Error bars represent standard 
deviation from three independent experiments. 
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The percentages of cell death in MEC1 cells at 48  hours after 
treatment with irradiation was 13.3 %, 14.4 % (10 µM and 100 µM) and 
7 %, 12.5 % (10 µM and 100 µM) at 72 hours when compared with 
untreated control samples (Fig 27). Analysis of the percentage of live 
cells in both the cell lines suggests that Daudi cells were more slightly 
more responsive to the inhibitor and irradiation treatment as compared 
to MEC1 cells. 
 
Figure 27: Assessment of radiosensitivity of MEC1 cells pre-
treated with SCR7. Bar graph showing the percentage of live MEC1 cells upon 
treatment with varied concentrations (10 µM and 100 µM) of SCR7 prior to 5 Gy 
irradiation to measure the sensitivity of cells to IR. The percentages of live cells were 
measured at 48 and 72 hours as previously described. Error bars represent standard 
deviation from three independent experiments.  
 
 
3.9 Investigation of effects on cell proliferation upon treatment 
with SCR7 inhibitor and irradiation 
 
To further understand the effects of SCR7 on cells, cell proliferation 
was measured using a BrdU assay (Roche, UK). The assay was 
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performed with HeLa, Daudi and MEC1 cell lines. The cells were 
treated with different concentrations (10 µM, 50 µM, 100 µM and 250 
µM) of inhibitor alone and also in combination with irradiation. Cells 
devoid of any SCR7 in the medium and only exposed to irradiation (5 
Gy) were used as controls. The proliferation was measured at 24, 48 
and 72 hours. The HeLa cells at 24 hours showed a low level of 
proliferation in all samples irrespective of treatment (Fig 28). The 
proliferation rate seemed to be enhanced at 48 hours in cells treated  
with inhibitor alone.  At 10 µM and 50 µM concentrations, the 
proliferation was low compared to the untreated control, however, at 
100 µM and  250 µM concentrations the cell growth was on par with 
the untreated control sample. In the samples treated with inhibitor and 
irradiation at 48 hours, the cell growth rate for  all concentrations 
except 50 µM and 100 µM, showed similar rates of proliferation as that 
of the untreated controls. However, in samples treated with 50 µM and 
100 µM concetrations of inhibitor and 5 Gy IR, there was a slight 
decrease in proliferation as shown in (Fig 28). At 72 hours the cell 
proliferation was highest and consistent among all samples. Indeed, 
cells  treated with high doses of inhibitor (100 µM and 250 µM) and 
irradiation, showed a slight enhancement of cell proliferation  when 
compared to untreated controls. In MEC1 cells the proliferation goes 
down at 24 hours in all treated and untreated samples. The cell 
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proliferation improves at 48 hours as compared to 24 hours across all 
the samples (Fig 29). At 48 hours, the proliferation of cells treated with 
inhibitor (10 µM, 50 µM, 100 µM, 250 µM) alone was high when compared 
to cells treated with a combination of inhibitor and irradiation. The 
samples treated with both the inhibitor and the irradiation had 
diminished cell proliferation compared to the untreated control samples 
at 48 hours (Fig 29).  
        
Figure 28: Results of a BrdU assay to assess cell proliferation of 
HeLa cells subjected to IR and SCR7 inhibitor. Bar graph showing the 
change in absorbance after treatment with varied concentrations (10 µM, 50 µM, 100 
µM, 250 µM) of Ligase 4 inhibitor SCR7 alone and in combination with irradiation (IR, 
5 Gy). The proliferation was measured at 24 hours, 48 hours and 72 hours. Error 
bars represent standard deviation from three independent experiments.  
  
 
At 72 hours the cell proliferation pattern was very similar to that at 48 
hours. However, at certain concentration of inhibitor (100 µM) and 
irradiation, the cell proliferation decreased visibly when compared to 
the untreated control. Neither MEC1 and HeLa cell proliferation seems 
to be affected ‘significantly’ by SCR7 inbitor treatment alone or in 
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combination with irradiation. In contrast, Daudi cells had a better 
response to inhibitor and irradiation treatment in terms of decreased 
cell proliferation. In Daudi cells, the rate of cell proliferation decreased 
gradually at high concentrations with inhibitor treatment alone (50 µM, 
100 µM, 250 µM) at 48 hours when compared to untreated control (Fig 
30). At 72 hours it was observed that Daudi cells treated with a high 
dose of inhibitor (250 µM) had reduced cell proliferation when 
compared to controls.  
   
Figure 29: BrdU assay measuring cell proliferation of MEC1 cells 
upon subjection to IR and SCR7 inhibitor. Bar graph showing the change 
in absorbance of HeLa cells upon treatment with varied concentrations (10 µM, 50 
µM, 100 µM, 250 µM) of Ligase 4 inhibitor SCR7 alone and in combination with 
irradiation (IR, 5 Gy). Error bars represent standard deviation from three independent 
experiments.  
 
 
 
 
Treatment of cells in combination with irradiation at all concentrations 
of the inhibitor resulted in lower rates of proliferation upon comparison 
with untreated cells at the all the time points suggesting that the 
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inhibitor along with irradiation has an additive effect on cell proliferation 
in Daudi cells. 
 
              
 
Figure 30: BrdU assay measuring cell proliferation of Daudi cells 
upon exposure to IR and SCR7 inhibitor. Bar graph showing the change 
in absorbance values of HeLa cells upon treatment with varied concentrations (10 
µM, 50 µM, 100 µM, 250 µM) of Ligase 4 inhibitor SCR7 alone and in combination 
with irradiation (IR, 5 Gy). The proliferation was measured at 24 hours, 48 hours and 
72 hours. Statistical analysis was performed using Two way anova, P value >0.0001 
for three independent experiments. Error bars represent standard deviation from 
three independent experiments.  
 
 
 72 
 
Chapter 4: Discussion 
 
Several studies have focused on the role of DNA ligases in             
cancer148-150. Two DNA ligases have been shown to be over 
expressed in cancers, DNA Ligase 1 in breast, lung, ovarian, sarcoma 
and neuroblastoma and DNA Ligase 3α in chronic myeloid         
leukemia148,149. Recent studies show that LIG4 gene expression is 
downregulated in 51 % of colorectal cancers due to abnormal 
promoter methylation activity151. Altered expression of the three DNA 
ligases has been associated with genetic instability44.  
 
One of the main aims of the project was to understand the role of DNA 
ligases in lymphoid malignancies. PCR Primers were designed to 
amplify LIG1, LIG3 and LIG4 mRNA and intial experiments were 
performed to identify optimal annealing temperature for each primer 
set using cDNA derived from K562 and MEC1 cell lines. Once 
optimised, the primers were used to determine the presence or 
absence of the ligases in CLL cases (Figs 16 & 17). Endpoint PCR 
experiments confirmed the expression of LIG1, LIG3 and LIG4 in a 
small cohort of randomly chosen CLL cases and the HS-5 cell line 
(Bone Marrow stromal cell line).                                                       
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Our studies were mainly focussed on the expression of the Ligase 4 
protein in Chronic Lymphocytic Leukemia. Interestingly, deficiency and 
mutations of Ligase 4 has been associated with LIG4 syndrome (as 
discussed in introduction), where patients are sensitive to irradiation 
and have increased risk of developing leukemia152. Initial experiments 
to asses the presence or absence of Ligase 4 protein, was done with a 
Ligase 4 antibody from Protein tech, UK (12695-1-AP). The protein 
was detected in the HeLa cell line (positive control) and also in MEC1, 
Daudi and HUT78 cell lines (Fig 18). These results were later 
confirmed using a second Anti-DNA Ligase IV antibody (ab26039) 
from Abcam, UK. The presence of Ligase 4 was detected in the 
positive control cell line, HeLa, and also MEC1 cell line, whereas in 
other cell lines such as Daudi and K562, protein could not be detected. 
(Fig 19). These discrepancies will have to further be analysed carefully 
to make solid conclusions from these studies. Nevertheless, one of the 
several reasons for the absence of Ligase 4 in certain cell lines might 
be due to changes in the extent of ongoing DNA damage, which might 
further activate the NHEJ pathway and result in a reduced need for 
Ligase 4 protein expression.  
 
HDACIs have been known to cause DNA damage and studies have 
shown that treatment with HDACIs increases the frequency of NHEJ 
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pathway145. ATPase Family AAA Domain Containing 5 (ATAD5), is a 
biomarker for identifying genotoxic compounds, its protein levels are 
known to increase upon increase in DNA damage153. Using an ATAD5 
luciferase assay, certain HDACIs were identified to cause potent DNA 
damage by inducing ROS153. Studies show that HDACI drugs escalate 
the NHEJ frequency because of the generation of DNA damage in the 
form of DSBs as observed in human cell lines. HDACIs did not show 
any specific changes in HR but did generate cellular resistance to 
HDACIs by keeping the cells alive145. Romidepsin is a HDACI which is 
licensed drug for treatment cutaneous T cell lymphomas144. Hence, 
Romidepsin resistant cell lines, such as RMEC1 and RHUT78, and 
wild type MEC1 and HUT78 cell lines were used to study ligase 4 
expression. Ligase 4 protein activity was low in the RMEC1 cell line 
and was not detected in RHUT78 cell line suggesting that the resistant 
cells, due to continuous exposure to the drug might have undergone 
chromatin remodelling, affecting the cellular signalling pathways 
(p21)154 thereby masking the Ligase 4 protein activity (Fig 20a).  
 
We also investigated the expression of another critical NHEJ protein, 
XRCC4. This protein works in unison with Ligase 4 during ligation of 
DNA strands61. XRCC4 protein expression was detected in all cell 
types used with very little variability. Further studies were focussed on 
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understanding the the influence of irradiation on Ligase 4 and XRCC4 
protein expression . We hypothesised that irradiation might induce 
DNA damage as radiation energy is directly absorbed by the DNA 
resulting in ionisation and breakage of the DNA strand. This should 
then trigger increased protein expression of Ligase 4 and XRCC4 
which are involved in the NHEJ pathway3,155. The amount of irradiation 
is directly proportional to the amount of DSBs produced156. The studies 
were carried out on MEC1 and HeLa cells at two different doses of 
irradiation (3 Gy and 5 Gy) over a range of incubation times (3, 6, 24, 
48 and 72 hours)157. Ligase 4 and XRCC4 protein expression was 
detected consistently across untreated and treated samples (Fig 22 & 
23). Simultaeneously, p53 protein expression was measured as an 
irradiation control146,147. This was detected in the MEC1 cell line but 
was very faint in the HeLa cell line.  
 
p53 protein disruption leads to a variety of cancers158,159 and studies 
have also shown that  cells exposed  to IR have increased amount of 
p53 expression which in turn leads to apoptosis147. From the results 
obtained we could not  form any meaningful conclusions as there was 
no significant change in Ligase 4 expression upon exposure to 
irradiation in MEC1 and HeLa cell lines. This may be due to high levels 
of radioresistance or alternate pathways of DNA repair. In the time 
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frame of the project it was not possible to quantitatively assess DSBs 
following irradiation. Interestingly, the HeLa cell line, which served as 
the positive control for Ligase 4 expression, had comparitively brighter 
bands when compared to MEC1 cells. 
 
There was no significant change in XRCC4 protein expression. A 
previous study described the expression of DNA repair proteins    
Ligase 4, XRCC4 and Ku 70/80 in human fibroblast cell lines derived 
from cancer patient samples who have undergone radiotherapy160. In 
this study, no significant difference (< 2 fold) was found upon 
comparing the protein expressions of Ligase 4, XRCC4, Ku 70/80 and 
DNA-PKcs,  thereby not showing much variation of expression among 
different samples160.  
 
Studying the expression of Ligase 4 and XRCC4 proteins in a random 
cohort of CLL patient samples suggests that Ligase 4 expression is 
variable in individual cases and may be worth pursuing to understand 
the significance and causes. XRCC4 expression, in contrast was 
ubiquitous and showed less variability cases 2932 and 2283 which 
showed Ligase 4 expression also had 11q22 deletion (Appendix) 
suggesting that such expression might be due to ongoing DNA 
damage. Some other cases which showed positive expression did not 
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have any common or specific genetic abnormalities in their clinical 
profile. Generation of more meaningful and definite conclusions will 
require a large cohort of samples with well defined clinical, genetic 
data and outcomes. 
 
Several studies indicate that disruption of the LIG4 gene results in the 
cells having increased sensitivity to ionising irradiation (as discussed in 
introduction)150. In addition to this, LIG4 has a key role in NHEJ and 
this pathway plays a major role in the development of resistance in 
cancer cells to radiation and chemotherapeutic drugs107. SCR7 is a 
compound that acts as an inhibitor of LIG4 and there is a suggestion 
that it can be used therapeutically124. SCR7 has high binding energy   
(-29.14 kcal/mol) to the DBD of Ligase 4 protein thereby disturbing its 
binding capacity to DSBs. Docking studies show that the binding of 
SCR7 inhibitor  to the Ligase 4 protein leads to a loss of hydrogen 
bond interactions between the Ligase 4 DBD and DNA124. This 
disruption results in the acumulation of DSBs thereby resulting in 
cytotoxicity in certain cell lines like Nalm6, a B cell precursor leukemia 
cell line124.   
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Another aspect of our study was to study the effects of a newly 
designed inhibitor of the NHEJ pathway, SCR7, on leukemic cell     
lines124. Using methods already published124, we tried to measure the 
cytotoxicity, radiosensitivity and  effect on cell proliferation of leukemic 
cell lines (Daudi and MEC1) after treatment with SCR7 inhibitor. Whilst 
investigating the cytotoxicity, the cell death increased by 32.88% in 
Daudi cells and 63.73% in MEC1 cells at very high concentration of 
250 µM of inhibitor alone (Fig 24 & 25) at 72 hours. Whereas at 24 
and 48 hours, the difference in cell death percentages were 
comparitively low. The reason behind elevated cell death may be 
attributed to exposure of cells to high doses of the drug rather than 
DNA damage as the percentage of cell death measured at 72 hours 
with and without irradiation in presence of SCR7 is abnormally high. 
 
We assesed if the Daudi and MEC1 cell lines could be sensitised to 
irradiation by treating them first with the SCR7 inhibitor (10 µM and 
100 µM) followed by irradiation (5 Gy) (Fig 26 & 27). We narrowed 
down the inhibitor concentration based on the previous results from 
cytotoxicity experiments which showed they did not result in rapid cell 
death (Fig 24 & 25). It has previously been suggested that  treatment 
with SCR7 followed by irradiation results in radiosensitivity and 
apoptosis124. In our study, cell death after irradiation treatment was 
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observed but in combination with SCR7, there was no significant 
change in cell death at varied time points in either Daudi and MEC1 
cells (Fig 26 & 27) implying that SCR7 treatment did not radiosensitise 
the cells effectively. Previous studies were performed on mouse 
models of breast adenocarcinoma where there was a 4 fold increase in 
the life span of animals treated with SCR7124, whereas in the Dalton 
Lymphoma mouse model, there was no change a in tumour growth or 
life span, which may explain our observation in leukemic and 
lymphoma cell lines. Cell proliferation assays carried out on MEC1, 
Daudi and HeLa cells showed that irradiation in combination with 
SCR7 inhibitor didn’t not have any potent effect on the proliferation of 
both HeLa and MEC1 cells (Fig 28 and 29). Only Daudi cells(Fig 30) 
had stunted proliferation rates when compared to their untreated 
controls suggesting that SCR7 inhibitor along with irradiation interfered 
with the cell cycle pattern.  
 
Future work 
 
In order for better understanding of ligase 4 expression, it will be 
crucial to  measure the gene expression of LIG4 in cell lines and 
primary cells by qPCR, and also upon treatment of irradiation to see 
whether the exposure triggers an increase in DNA repair thereby 
upregulating LIG4 expression. Gene expression of LIG4 by qPCR in a 
wider cohort of CLL patient samples with defined genetic abnormalities 
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and who have undergone chemotherapeutic treatment may provide 
further insights. These set of experiments will enable us to understand 
if genetic abnormalities and chemotherapy affect the DNA repair 
processes in CLL patients. Lastly, it would be important to investigate 
the cytoxic or radiosensitising  effects of the SCR7 drug on cells with 
parallel assays that allow quantitative estimation of DSBs to allow 
meaningful correlations and it is possible that other existing novel 
inhibitors of critical proteins in the DNA repair pathways may still be 
relevant in the treatment of Chronic Lymphocytic Leukemia and indeed 
other haematological malignancies. 
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Appendix 
 
                   
Table 6: Clinical data of all the CLL patients used in the project. 
 
 
                   
Table 7: Raw data of radiosensitivity assay as shown in (Figures 
26 and 27) 
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Table 8: Raw data values of cytotoxicity assays for Daudi and 
MEC1 cells at 24 , 48 and 72 hours (Figure 24 & 25). 
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